Riliprubart Prefilled Pen (PFP)

Phase 3

Riliprubart Prefilled Pen (PFP) is one of 2 therapeutic programs targeting Polyneuropathy, Inflammatory Demyelinating, Chronic. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Polyneuropathy, Inflammatory Demyelinating, ChronicEnrolling by invitation

Polyneuropathy, Inflammatory Demyelinating, ChronicPhase 3

Enrolling by invitation

Competition

Competitive Landscape

1 competitor in Polyneuropathy, Inflammatory Demyelinating, Chronic

#DrugCompanyPhaseTrials

Riliprubart

Sanofi

Phase 3

1 2

Riliprubart Prefilled Pen (PFP)

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Polyneuropathy, Inflammatory Demyelinating, Chronic1 trial

Long-term Extension Study to Evaluate the Safety and Efficacy of Riliprubart (SAR445088) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Enrolling by invitation· Sanofi logo

Sanofi·Phase 3·NCT06859099·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Riliprubart Prefilled Pen (PFP). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Riliprubart Prefilled Pen (PFP). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Sanofi

Riliprubart Prefilled Pen (PFP)

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Polyneuropathy, Inflammatory Demyelinating, Chronic1 trial

References

Drug Info

Quick Facts

Related News